Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH Z FORSTOT

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1144323023
CMS profile
233505
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,833.15

200 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,738.91 198
Education $94.24 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH Z FORSTOT

NPI 1144323023 · CMS profile ID 233505

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144323023?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144323023?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144323023?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144323023?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

200 matching records · $3,833.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 200 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 200.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $24.7006/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078398459 CMS
ABBVIE INC. $31.1206/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744323 CMS
Novartis Pharmaceuticals Corporation $13.3806/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086859467 CMS
UCB, Inc. $22.2206/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209981 CMS
UCB, Inc. $1.3206/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209976 CMS
Alexion Pharmaceuticals, Inc. $29.3206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093913250 CMS
Mallinckrodt Hospital Products Inc. $34.2106/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145072324 CMS
PFIZER INC. $21.6506/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132048166 CMS
PFIZER INC. $2.9406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132060420 CMS
UCB, Inc. $18.1806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209972 CMS
ABBVIE INC. $18.7806/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744321 CMS
Amgen Inc. $20.6206/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111576576 CMS
E.R. Squibb & Sons, L.L.C. $11.4006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101226773 CMS
E.R. Squibb & Sons, L.L.C. $1.1906/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101226775 CMS
SCILEX PHARMACEUTICALS INC. $19.0706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136248654 CMS
Janssen Biotech, Inc. $22.2805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078397428 CMS
AstraZeneca Pharmaceuticals LP $18.1605/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104526382 CMS
Radius Health, Inc. $9.8105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089963529 CMS
UCB, Inc. $25.8905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209967 CMS
Mallinckrodt Hospital Products Inc. $33.8705/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145072315 CMS
Mallinckrodt Hospital Products Inc. $3.0105/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145072320 CMS
ABBVIE INC. $15.6405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744319 CMS
UCB, Inc. $17.2705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209963 CMS
UCB, Inc. $0.1605/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209954 CMS
UCB, Inc. $1.0905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209958 CMS
Amgen Inc. $19.5305/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111576574 CMS
Radius Health, Inc. $30.3505/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089963534 CMS
E.R. Squibb & Sons, L.L.C. $22.1505/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101226769 CMS
Lilly USA, LLC $21.4705/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135082744 CMS
SOBI, INC $19.2505/13/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141421293 CMS
Fresenius Kabi USA, LLC $13.9005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146948695 CMS
Janssen Biotech, Inc. $14.0805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078397164 CMS
Mallinckrodt Hospital Products Inc. $6.3105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145072312 CMS
ABBVIE INC. $16.8205/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744317 CMS
GlaxoSmithKline, LLC. $22.8005/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116645464 CMS
Janssen Biotech, Inc. $74.9905/03/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078397487 CMS
Janssen Biotech, Inc. $16.6805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078398238 CMS
PFIZER INC. $19.1105/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132044054 CMS
PFIZER INC. $0.9805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132058246 CMS
ABBVIE INC. $125.0005/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744315 CMS
E.R. Squibb & Sons, L.L.C. $18.2004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101226763 CMS
Novartis Pharmaceuticals Corporation $9.0304/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086859463 CMS
Radius Health, Inc. $26.1504/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089963523 CMS
Alvogen Inc $25.2304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137624260 CMS
ABBVIE INC. $13.4204/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744313 CMS
Janssen Biotech, Inc. $17.0704/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078398932 CMS
Amgen Inc. $5.0604/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111576608 CMS
UCB, Inc. $23.2404/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143209949 CMS
Amgen Inc. $24.5304/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111576604 CMS
ABBVIE INC. $22.1804/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744311 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,915.08 188
PY2020 $635.50 39
PY2021 $2,292.87 154
PY2022 $2,784.76 157
PY2023 $2,935.77 145
PY2024 $3,833.15 200
PY2025 $3,170.76 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,503.55 26
PY2024 Principal investigator $127,936.30 29
PY2023 Principal investigator $248,268.68 39
PY2022 Principal investigator $189,820.29 31
PY2021 Principal investigator $126,690.30 27
PY2020 Recipient $1,508.81 1
PY2020 Principal investigator $124,704.23 38
PY2019 Principal investigator $263,203.20 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,062.95 11/04/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520193
Principal investigator 1 ABBVIE INC. $2,543.83 11/04/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520195
Principal investigator 1 ABBVIE INC. $12,300.43 10/23/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202518215
Principal investigator 1 ABBVIE INC. $2,488.75 10/09/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513895
Principal investigator 1 ABBVIE INC. $6,940.00 09/18/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202511592
Principal investigator 1 ABBVIE INC. $7,880.00 09/04/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202509916
Principal investigator 1 ABBVIE INC. $2,303.80 09/03/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508302
Principal investigator 1 ABBVIE INC. $2,284.63 08/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202502086
Principal investigator 1 ABBVIE INC. $4,741.25 08/05/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502088
Principal investigator 1 ABBVIE INC. $7,270.50 07/02/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494445
Principal investigator 1 ABBVIE INC. $2,252.50 07/02/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494447
Principal investigator 1 ABBVIE INC. $890.00 06/11/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202490863
Principal investigator 1 ABBVIE INC. $380.00 06/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488207
Principal investigator 1 ABBVIE INC. $1,847.50 06/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488281
Principal investigator 1 ABBVIE INC. $2,968.15 05/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481453
Principal investigator 1 ABBVIE INC. $2,348.35 05/06/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481455
Principal investigator 1 ABBVIE INC. $1,978.18 05/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202481457
Principal investigator 1 ABBVIE INC. $4,880.30 04/03/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202470885
Principal investigator 1 ABBVIE INC. $6,354.50 04/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202470889
Principal investigator 1 ABBVIE INC. $2,348.35 03/06/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456478
Principal investigator 1 ABBVIE INC. $1,120.65 03/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202456481
Principal investigator 1 ABBVIE INC. $302.20 03/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202456485
Principal investigator 1 ABBVIE INC. $4,763.80 02/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202443934
Principal investigator 1 ABBVIE INC. $4,739.90 02/05/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202443942
Principal investigator 1 ABBVIE INC. $1,982.43 02/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202443945
Principal investigator 1 ABBVIE INC. $2,530.60 01/02/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433443